Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial

被引:498
作者
Van de Werf, F [1 ]
Ross, A [1 ]
Armstrong, P [1 ]
Granger, C [1 ]
机构
[1] Univ Hosp Gasthuisberg, Dept Cardiol, B-3000 Louvain, Belgium
关键词
D O I
10.1016/S0140-6736(06)68147-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Primary percutaneous coronary intervention (PCI) is more effective than fibrinolytic therapy for ST-segment elevation acute myocardial infarction (STEMI), but time to intervention can be considerable. Our aim was to investigate whether the administration of full-dose tenecteplase before a delayed PCI could mitigate the negative effect of this delay. Methods We did a randomised study in which we assigned patients with STEMI of less than 6 It duration (scheduled to undergo primary PCI with an anticipated delay of 1-3 h) to standard PCI (n=838) or PCI preceded by administration of full-dose tenecteplase (n=829). All patients received aspirin and a bolus, without an infusion, of unfractionated heparin. Our primary endpoint was death or congestive heart failure or shock within 90 days. Analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00168792. Findings We planned to enrol 4000 patients, but early cessation of enrolment was recommended by the data and safety monitoring board because of a higher in-hospital mortality in the facilitated than in the standard PCI group (6% [43 of 664] vs 3% [22 of 656], p=0.0105). Of those enrolled, six were lost to follow-tip in the facilitated PCI group and seven in the other group. Median time from randomisation to first balloon inflation was similar in both groups. The median time from bolus tenecteplase to first balloon inflation was 104 min. We noted the primary endpoint in 19% (151 of 810) of patients assigned facilitated PCI versus 13% (110 of 819) of those randomised to primary PCI (relative risk 1.39, 95% CI 1.11-1.74; p=0.0045). During hospital stay, significantly more strokes (1.8% [15 of 8291 A vs 0, p<0.0001), but not major non-cerebral bleeding complications (6% [46 of 829] vs 4% [37 of 838], p=0.3118), were reported in patients assigned facilitated rather than standard PCI. We also noted more ischaemic cardiac complications, such as reinfarction (6% [49 of 805] vs 4% [30 of 820], p=0.0279) or repeat target vessel revascularisation (7% [53 of 805] vs 3% [28 of 818], p=0.0041) within 90 days in this study group. Interpretation A strategy of full-dose tenecteplase with antithrombotic co-therapy, as used in this study and preceding PCI by 1-3 h, was associated with more major adverse events than PCI alone in STEMI and cannot be recommended.
引用
收藏
页码:569 / 578
页数:10
相关论文
共 33 条
[1]   Task force 1: The ACCF and AHA codes of conduct in human subjects research [J].
Adams, RJ ;
Antman, EM ;
Kavey, REW .
CIRCULATION, 2004, 110 (16) :2512-2516
[2]   Prehospital versus periprocedural administration of abciximab in STEMI:: early and late results from the randomised REOMOBILE-study [J].
Arntz, HR ;
Schröder, JF ;
Peis, K ;
Schwimmbeck, P ;
Witzenbichler, B ;
Schultheiss, HP .
EUROPEAN HEART JOURNAL, 2003, 24 :268-268
[3]   Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction [J].
Cutlip, DE ;
Ricciardi, MJ ;
Ling, FS ;
Carrozza, JP ;
Dua, V ;
Garringer, J ;
Giri, S ;
Caputo, RP .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (08) :977-980
[4]   Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome -: Results from the French Nationwide USIC 2000 Registry [J].
Danchin, N ;
Blanchard, D ;
Steg, PG ;
Sauval, P ;
Hanania, G ;
Goldstein, P ;
Cambou, JP ;
Guéret, P ;
Vaur, L ;
Boutalbi, Y ;
Genès, N ;
Lablanche, JM .
CIRCULATION, 2004, 110 (14) :1909-1915
[5]   ACTIVATION OF PROTHROMBIN ACCOMPANYING THROMBOLYSIS WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR [J].
EISENBERG, PR ;
SOBEL, BE ;
JAFFE, AS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 19 (05) :1065-1069
[6]   Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: Design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial [J].
Ellis, SG ;
Armstrong, P ;
Betriu, A ;
Brodie, B ;
Herrmann, H ;
Montalescot, G ;
Neumann, FJ ;
Smith, JJ ;
Topol, E .
AMERICAN HEART JOURNAL, 2004, 147 (04) :684-8
[7]  
Fernández-Avilés F, 2004, EUR HEART J, V25, P33
[8]   Early administration of abciximab bolus in the emergency room improves microperfusion after primary percutaneous coronary intervention, as assessed by TIMI Frame Count:: results of the ERAMI trial [J].
Gabriel, HM ;
Oliveira, J ;
da Silva, PC ;
da Costa, JM ;
da Cunha, JAC ;
França, C ;
Vagueiro, MC .
EUROPEAN HEART JOURNAL, 2003, 24 :543-543
[9]   Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction - Is the slope of the curve the shape of the future? [J].
Gersh, BJ ;
Stone, GW ;
White, HD ;
Holmes, DR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (08) :979-986
[10]  
Giugliano RP, 2004, CIRCULATION, V110, P696